3.23
price down icon0.31%   -0.01
after-market 시간 외 거래: 3.22 -0.010 -0.31%
loading

Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스

pulisher
Jun 18, 2025

Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan

Jun 18, 2025
pulisher
Jun 17, 2025

Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks

Jun 17, 2025
pulisher
Jun 16, 2025

APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Aptevo Sends Business Development Team to BIO 2025: Major Partnership Opportunities Ahead - Stock Titan

Jun 13, 2025
pulisher
May 29, 2025

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World

May 29, 2025
pulisher
May 25, 2025

Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus

May 25, 2025
pulisher
May 23, 2025

Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks

May 23, 2025
pulisher
May 22, 2025

Aptevo Therapeutics Announces Reverse Stock Split - TipRanks

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire

May 22, 2025
pulisher
May 22, 2025

Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan

May 22, 2025
pulisher
May 18, 2025

StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World

May 18, 2025
pulisher
May 16, 2025

Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 15, 2025

Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aptevo reports high remission in AML patients with new drug - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire

May 15, 2025
pulisher
May 14, 2025

Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan

May 14, 2025
pulisher
May 12, 2025

Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World

May 12, 2025
pulisher
May 10, 2025

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World

May 10, 2025
pulisher
May 08, 2025

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus

May 08, 2025
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
자본화:     |  볼륨(24시간):